Net Health and Osiris Therapeutics Announce the Broad Availability of Grafix® to Wound Care Patients Due to WoundExpert® EM...
October 11 2016 - 4:30PM
Net Health, the leading provider of software solutions for
specialized outpatient care, announced today that their partnership
with Osiris Therapeutics, Inc. (Nasdaq:OSIR), has made Grafix®, a
viable cryopreserved placental membrane, more widely available for
use in acute and chronic wound treatment in outpatient wound care
centers throughout the United States. Grafix is currently marketed
for use as a wound allograft cover/barrier.
Net Health’s WoundExpert® EMR serves 90 percent of US outpatient
wound care facilities that use specialized electronic
documentation. Since implementing a full integration between Grafix
and the Cell and Tissue Based Product section of WoundExpert’s
Connections module, providers at these client sites can now verify
patients’ insurance eligibility for Grafix in rapid time while
maintaining all data and communications securely in the electronic
medical record.
Increased speed of clinical documentation due to faster
processing and authorization is the key advantage of this model.
The insurance verification form is completed inside WoundExpert,
patient data pre-populates and takes a fraction of the time
providers were accustomed to when previously dealing with matters
of eligibility.
Anthony Sanzo, Net Health CEO, explains his view on the benefit
to their clients, “We are pleased to facilitate the ready
availability of a market-leading tissue product that providers want
to use—when appropriate for the patient. This model works because
rapid payer approval is time saving for the staff at the facility
and also accelerates initiation of the patient’s treatment.”
Osiris Vice President of Marketing, Jason Keefer, says the
company is positive about the future of the relationship.
“Providers want to use products that are beneficial, but time
consuming coverage and reimbursement verification constraints can
delay the course of treatment. This integration between Grafix and
WoundExpert brings speed and transparency to the availability of
Grafix on a case-by-case basis. Plus, with all related
communications and documentation secured inside the WoundExpert
medical record, we are streamlining a formerly cumbersome process
that involved faxes, voice mail, and multi-day wait periods, and
doing so in a way that ensures compliance.”
For more information on WoundExpert, visit
nethealth.com/See-WoundExpert.
About Net Health
Net Health is the leader in software solutions for specialized
outpatient care. Known for being experts in The Art of the Right
Fit®, fully interoperable EHR solutions serve five medical
specialty markets. Offering clients an end-to-end solution that
includes practice management tools, clinical workflow
documentation, revenue cycle management, and analytics, Net Health
serves healthcare professionals in 3,700 urgent care, wound care,
physical therapy, speech and language therapy, occupational
therapy, occupational medicine, employee health, and workplace
medicine facilities. Net Health is committed to strengthening
patient care, outcomes, and facility performance. Learn more at
nhsinc.com. Net Health is a Spectrum Equity portfolio company.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a
world leader in researching, developing and marketing regenerative
medicine products that improve health and lives of patients and
lower overall healthcare costs. Having developed the world's first
approved stem cell drug, the company continues to advance its
research and development in biotechnology by focusing on innovation
in regenerative medicine - including bioengineering, stem cell
research and viable tissue based products. Osiris has achieved
commercial success with products in orthopaedics, sports medicine
and wound care, including BIO4®, Cartiform®, Grafix®, TruSkinTM and
StravixTM. Osiris, Grafix, Cartiform, TruSkin, and Stravix
are trademarks of Osiris Therapeutics, Inc. BIO4® is a trademark of
Howmedica Osteonics Corp. More information can be found on the
company's website, www.Osiris.com. (OSIR-G).
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include statements about our
expectations, beliefs, plans, objectives, intentions, assumptions
and other statements that are not historical facts. Words or
phrases such as "anticipate," "believe," "continue," "ongoing,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project" or similar words or phrases, or the negatives
of those words or phrases, may identify forward-looking statements,
but the absence of these words does not necessarily mean that a
statement is not forward-looking. Examples of forward-looking
statements may include, without limitation, statements regarding
the anticipated efficiencies and advantages of new services and the
likelihood of customer adoption of new services. Forward-looking
statements are subject to known and unknown risks and uncertainties
and are based on potentially inaccurate assumptions that could
cause actual results to differ materially from those expected or
implied by the forward-looking statements. Accordingly, you should
not unduly rely on these forward-looking statements. We undertake
no obligation to publicly revise any forward-looking statement to
reflect circumstances or events after the date of this press
release or to reflect the occurrence of unanticipated events.
For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Sep 2023 to Sep 2024